About
Partner with over three decades in biotech focused on translating scientific discoveries into therapies. Co-founded Sporos Bioventures as CSO and previously spent 12 years at AVEO Oncology including as Chief Scientific Officer.
Experience
- Cure VenturesPartnercurrent2023 — presentBoston
- Sporos BioventuresChief Scientific Officer, Co-founder2019 — 2023Houston, Boston
- Tvardi TherapeuticsChief Scientific Officer and Chair of Scientific Advisory Board2018 — 2023Houston, TX
- Trieza TherapeuticsChief Scientific Officer2018Cambridge, MA
- Quiet TherapeuticsExecutive Vice President/Chief Scientific Officer2016 — 2017Lexington, Massachusetts
- AVEO OncologyChief Scientific Officer2003 — 2015Cambridge, MA
- GPC Biotech Inc./Mitotix Inc.Vice President1993 — 2002Cambridge, MA
Education
- Harvard Medical School - Massachusetts General HospitalPostdoctoral fellow
- University of Szeged
Skills & more
Management2Oncology6Biotechnology6Drug Development4Life Sciences8Molecular Biology6Biochemistry2Clinical Development2Drug Discovery3Cell Biology1Cell CultureImmunology1
+1 more
Pharmaceutical IndustryFrom Jeno's professional profile.
Same school
Also attended Harvard Medical School - Massachusetts General Hospital3
Shared employers
Also worked at Sporos Bioventures1
Also worked at AVEO Oncology2
Colleagues at Cure Ventures
Albert J. Robichaud
Partner at Cure Ventures
Annie Mitsak
Partner at Cure Ventures
Bill Amsbaugh
CTO and Partner at Cure Ventures
Courtney Turner
Director of Finance at Cure Ventures
David Fallace
Managing Partner at Cure Ventures
Dr. Michael Aberman
Investor at Cure Ventures
Dr. Milenko Cicmil
Investor at Cure Ventures
Drew King
CFO and Partner at Cure Ventures